International Digital Health Vendor Evaluation

International Digital Health Vendor Evaluation

A defensible international digital health decision is a collection of local evidence, not one global approval. Start with one function, one country, one care setting, one product version, and one accountable decision group. Expand only when the next country and workflow pass their own legal, clinical, data, interoperability, security, support, and change-control gates.

This guide is for healthcare technology research and procurement planning. It is not medical, clinical, legal, privacy, security, regulatory, billing, coding, reimbursement, or compliance advice. It reports no product tests, customer interviews, local performance measurements, certifications, authorizations, service levels, implementation times, or financial results. Qualified local owners must determine what applies and whether the evidence is adequate.

Gate 1: define the exact function and use

Inventory each software function before reviewing the company as a whole. Record the intended user, patient or population, input, output, purpose, downstream action, care setting, product and model version, configuration, connected systems, and person who can pause the workflow. Separate clinical, administrative, communication, storage, analytics, AI, EHR, device, and support functions because they may trigger different evidence and authority paths.

The WHO classification of digital interventions, services and applications in health provides a shared language for describing the problem, intervention, capability, service, and application type. It does not determine clinical effectiveness, regulatory status, local fit, or legal applicability. A vendor category or product label cannot replace the function inventory.

Write exclusions beside the approved scope. Name the countries, languages, sites, specialties, users, data sources, devices, workflows, decisions, and versions that were not reviewed. A statement such as “human in the loop” is incomplete unless the record shows who reviews what evidence, when intervention occurs, how disagreement is captured, and which action remains outside the software.

Stop condition — a function, intended use, downstream action, version, country, excluded use, or accountable owner is undefined.

Gate 2: map country and applicability

Create one jurisdiction row for every country or region in the proposed rollout. Record the buyer and vendor entities, care setting, processing purpose, exact function, patient and workforce populations, product category asserted by the vendor, hosting and support locations, official authority, text or policy version, effective or transition date, local reviewer, and next reassessment date.

The WHO Global strategy on digital health 2020–2027 supports aligning digital health with national or regional strategy and financial, organizational, human, and technical resources. The WHO Digital Implementation Investment Guide supports needs-based planning aligned with country readiness, national architecture, health-system goals, and a costed implementation plan. Neither source determines product authorization, local law, vendor approval, or outcomes.

For an EU branch, the official EU Artificial Intelligence Act and the European Commission European Health Data Space overview can identify questions about system role, scope, transition dates, EHR functionality, interoperability, security, and later implementing acts. Their existence does not establish local legal applicability, prove that every obligation is already applicable, or extend EU rules to another jurisdiction.

For a United States device-policy branch, the FDA Digital Health Policy Navigator helps identify policy questions for each software function. Its result is not a formal FDA device determination, market authorization, clearance, approval, safety finding, or local procurement decision.

Stop condition — the responsible local legal, regulatory, privacy, clinical, or security owner cannot identify the governing authority, current text, role, effective date, or decision record.

Gate 3: trace data roles and cross-border transfers

Draw the real data flow rather than relying on a hosting-region answer. For each patient, workforce, clinical, consent, device, identity, audit, telemetry, billing, support, and derived-data element, record the source system, destination, purpose, recipient, access method, hosting, backup, support location, subprocessor, onward transfer, remote access, retention, deletion, correction, export, and incident path.

The OECD Recommendation on Health Data Governance supports questions about personal health data governance, privacy, security, interoperability, and cross-border cooperation. It is a policy recommendation, not a transfer authorization, legal opinion, or organization-level certification.

For an EEA outbound-transfer branch, the EDPB international data transfers guidance supports identifying exporter, importer, transfer criteria, adequacy or safeguards, rights, contracts, and transfer impact evidence when the GDPR branch applies. A standard contractual clause or adequacy route does not close lawful-processing, minimization, security, recipient, subprocessor, or local legal review.

For a United States HIPAA branch, HHS OCR business associate guidance supports identifying covered entity, business associate, subcontractor, PHI flow, and required agreement terms when those definitions apply. A BAA is not proof of security or complete compliance, and HIPAA does not govern every health-data relationship.

Stop condition — a data class, recipient, role, location, purpose, transfer route, subprocessor, retention rule, or authorized owner remains unknown.

Gate 4: match clinical and regulatory evidence

Build one evidence-fit row for every safety, performance, clinical, or workflow claim the decision group plans to rely on. Compare the exact function, product and model version, country, authorization record when applicable, population, language, site type, specialty, care pathway, user, device and connectivity environment, data source, outcome, limitation, and date with the proposed use.

When a function may fall within Software as a Medical Device scope, the IMDRF SaMD Clinical Evaluation document supports asking about valid clinical association, analytical or technical validation, and clinical validation. It does not decide local device status, grant market access, certify a product, or prove safe and effective performance in the buyer setting.

The WHO ethics and governance of artificial intelligence for health supports questions about autonomy, safety, transparency, accountability, inclusiveness, equity, responsiveness, and sustainability when AI is in scope. These principles do not certify an AI system or replace product-specific clinical, regulatory, human-factors, privacy, or local workflow evidence.

Treat regulator records, peer-reviewed studies, vendor studies, customer references, attestations, and buyer-observed tests as different evidence types. Record who produced the evidence, what was excluded, whether negative findings are available, and what local work remains. Do not convert a marketing summary into independent validation.

Stop condition — a relied-on claim cannot be matched to the proposed function, country, population, language, workflow, environment, configuration, version, or consequence of error.

Gate 5: test localization and equity

Separate interface translation from clinical and operational localization. Verify language variant, reading level, terminology and code systems, local clinical or public-health content, consent and patient communications, date and number formats, accessibility, right-to-left behavior when relevant, low-bandwidth and offline paths, device constraints, identity practices, local payer or ministry workflow, and escalation language.

Use local subject-matter owners to approve terminology, content, user authority, and safety-critical communications. Test ordinary users and difficult conditions, including incomplete translation, mixed-language records, unavailable terminology service, low connectivity, older devices, assistive technology, and a user who cannot access the assumed support channel.

WHO strategy and ethics sources support country fit, equity, autonomy, and responsible governance questions. They do not prove that translation is accurate, that a local pathway is represented correctly, or that a product performs equally across populations. Translation completion is not localization approval.

Record the evidence country, population, language, workflow, environment, and version beside the proposed deployment. Differences stay visible and drive a local test plan instead of being averaged away.

Stop condition — safety-critical content, user authority, accessibility, connectivity, population fit, or local workflow cannot be validated by an accountable local owner.

Gate 6: verify interoperability and exit

Ask for the exact exchange standard release, CapabilityStatement, profiles, Implementation Guides, extensions, terminology and value-set versions, authentication method, endpoint behavior, configuration, rate limits, provenance, consent, audit, identity, and error-handling documentation used by the proposed deployment.

HL7 FHIR conformance rules explain why a conformance claim is meaningful only for a stated exchange framework and specific resource usage. Base FHIR allows optional features and does not guarantee that two systems interoperate, preserve local semantics, meet a national profile, fit a workflow, or protect patient and data safety.

Build local tests for send, receive, search, update, export, correction, terminology mapping, identity matching, consent enforcement, provenance, audit, round trip, duplicate, delay, malformed message, unavailable dependency, retry, reconciliation, and recovery. Store expected and observed behavior separately; a standard, logo, API, or self-attestation belongs in the evidence column, not the result column.

Test exit before contract signature. Require usable export formats, field and terminology documentation, attachments and audit history, deletion or return evidence, transition assistance, time and cost owners, and downstream reconciliation. A technically available export is not portable if the buyer cannot interpret, validate, or safely import it.

Stop condition — a required exchange, semantic field, identity, consent, provenance, audit, exception, recovery, export, or termination path cannot be tested and reconciled.

Gate 7: prove cyber, support, and continuity

Map buyer, vendor, hosting provider, subprocessor, implementation partner, and local support responsibilities. Request evidence for access, privileged operations, logging, vulnerability handling, secure development, dependency and supply-chain risk, backup, restore, incident detection, notification, containment, recovery, business continuity, and reassessment after material change.

The voluntary NIST Cybersecurity Framework 2.0 can organize Govern, Identify, Protect, Detect, Respond, and Recover outcomes. It is not a certification, compliance conclusion, penetration-test result, security guarantee, or avoided-loss value.

Turn support claims into observable tests. Record supported languages and time zones, severity definitions, intake paths, response and restoration evidence, escalation layers, local-partner dependencies, planned maintenance, status communication, after-hours ownership, downtime procedure, manual fallback, recovery sequence, and reconciliation. Do not treat “24/7” as evidence until the proposed route and severity are exercised.

Test at least one integration failure, permission problem, delayed response, support escalation, backup restore, downtime process, and recovery handoff. Preserve timestamps, participants, observed behavior, missing documentation, corrective action, and retest result.

Stop condition — the team cannot detect, escalate, operate through, recover from, and reconcile a material incident without undocumented vendor action.

Gate 8: control lifecycle and country expansion

Maintain a change register for software and model version, training or reference data, threshold, intended use, population, country, language, clinical content, hosting region, subprocessor, interface, terminology, security control, support location, contract term, regulatory status, and end-of-life date. Define notice, impact assessment, regression test, approval, rollout, rollback, user communication, and historical traceability for each class.

The voluntary NIST AI Risk Management Framework can help teams assign governance, map context and affected roles, measure risks and benefits, manage incidents and third parties, and revisit change and retirement when AI is in scope. It is not certification, regulatory approval, clinical validation, legal advice, or a fixed healthcare control set.

Classify changes as documentation-only, review-required, pause-triggering, or approval-resetting before go-live. Country expansion is an approval-resetting event unless accountable owners document why every relevant function, authority, data flow, population, language, workflow, integration, support path, and version remains within the reviewed boundary.

Set an expiration or renewed-review date for every decision. Preserve rejected evidence, failed tests, open issues, incidents, and abandoned approaches so a later reviewer can reconstruct why the boundary exists.

Stop condition — the organization cannot identify the deployed version, assess a material change, trace historical output, notify affected owners, regression test, pause rollout, rollback, or reopen country review.

Procurement questions to ask

Assign each question to a named owner and keep the requested evidence beside the answer. A meeting response without a document, test, or accountable observation remains a vendor assertion.

Regional operations and local clinical owners

• What exact function, users, patient population, country, care setting, language, workflow, downstream action, product version, and exclusion are under review?
• Which local clinical, public-health, operational, consent, terminology, accessibility, and safety requirements must be represented, and who approves each one?
• Which ordinary and difficult cases must be tested, and what harm, inequity, workflow failure, or unresolved evidence would stop the pilot or expansion?

Privacy, legal, regulatory, and data-governance reviewers

• Which buyer, vendor, partner, hosting, support, and subprocessor entities receive or access each data class, in which country, for what purpose and retention period?
• Which current local authority, role, lawful basis or equivalent, transfer mechanism, product status, contract term, and effective date apply to each function and flow?
• Which patient or data-subject access, correction, restriction, consent, deletion, complaint, incident, audit, and regulator-notification paths must the deployment support?

Architecture, interoperability, and security owners

• Which standard release, CapabilityStatement, profile, Implementation Guide, terminology, extension, authentication, provenance, consent, identity, and audit behavior does the proposed version implement?
• How will normal exchange, malformed or delayed data, duplicates, dependency failure, retry, downtime, export, restore, reconciliation, and exit be tested and evidenced?
• Which access, privileged-action, logging, vulnerability, dependency, backup, incident, continuity, recovery, and residual-risk controls are divided between buyer and vendor?

Procurement, finance, implementation, and support owners

• Which implementation, localization, integration, validation, training, monitoring, support, revalidation, migration, and exit responsibilities and costs belong to each party?
• Which languages, time zones, severity definitions, response and restoration paths, escalation layers, local partners, maintenance windows, and end-of-life commitments are evidenced rather than promised?
• Which failed gate is a disqualifier, which open item can be conditional, who accepts residual risk, and what evidence triggers renewal, expansion, pause, remediation, or exit?

Buyer-owned artifacts

These artifacts make the internal decision reconstructable. They are not a certification, not legal or clinical approval, and not a vendor ranking. Every row records a status of pass, fail, conditional, or open, plus owner, source and version, evidence link, observed date, review or expiry date, limitation, and next action. Keep vendor assertions separate from buyer-observed and regulator-verified evidence.

Jurisdiction applicability matrix

Create one row per country, function, and entity relationship. Record care setting, buyer and vendor entities, accountable local owner, intended use, user and population, product category, data role, hosting and support locations, privacy, data, device, AI, EHR and cyber branches, official authority, source version and date, claimed market status, evidence, status, exclusion, review date, and change trigger.

Use applicable, not applicable with rationale, or open for every branch. If the responsible local owner cannot determine the branch, mark “open — local owner/evidence required.” HealthAIdir does not supply the legal or regulatory conclusion.

Cross-border data-flow and transfer register

Create one row per data class and system boundary. Record source, destination, purpose, recipient, role, hosting, backup, support and subprocessor countries, onward transfer, remote access, mechanism supplied by the local owner, access, correction, retention, deletion, incident path, evidence date, and reassessment trigger.

A contract clause, adequacy route, BAA, hosting statement, or vendor diagram is evidence to review, not the complete finding. Any unknown recipient, access path, location, purpose, retention rule, or onward transfer keeps the flow open.

Evidence transferability and localization matrix

Create one row per relied-on result or localization claim. Record the evidence country, site, population, language, specialty, workflow, user, device and connectivity environment, data source, product version, outcome, limitation, and date beside the proposed deployment values.

Describe every material difference, local validation required, exclusion, reviewer, failure threshold, observed result, and expansion-reset rule. A translation certificate or customer reference from another setting does not establish clinical content accuracy, accessibility, equity, or local fit.

Interoperability and exit test matrix

Create one row per required exchange, field, terminology, identity, consent, provenance, audit, exception, recovery, export, and exit path. Record the exact standard and implementation version, source and destination, configuration, precondition, test-data boundary, expected behavior, observed behavior, timestamp, reviewer, evidence link, discrepancy, correction, downstream effect, detectability, reconciliation, and decision.

Store the CapabilityStatement, profile, Implementation Guide, mapping, and vendor documentation as inputs. Only observed, version-matched local tests belong in the result column.

Operating and change-control decision packet

Combine the approved scope, jurisdiction rows, data-flow map, evidence-fit findings, localization results, interoperability tests, security and support evidence, implementation plan, contract findings, incidents, changes, disqualifiers, open evidence, residual-risk owners, and renewal date.

Record pass, fail, conditional, and open separately. Do not create a default numeric score or allow price and features to average away a failed legal, privacy, safety, security, integrity, interoperability, audit, continuity, recovery, or exit gate. The decision belongs to an accountable internal group, not a vendor presentation.

FAQs

Can a vendor be globally compliant?

No. Applicability depends on the specific country, entities, roles, function, intended use, data, processing purpose, transfer, product status, care setting, contract, effective date, and local interpretation. Ask the vendor for scoped evidence, then require authorized local owners to decide each jurisdiction row.

Does FHIR support prove interoperability?

No. FHIR defines exchange resources and conformance mechanisms, but optionality and local implementation choices matter. Verify the exact release, CapabilityStatement, profiles, Implementation Guides, terminology, configuration, fields, exceptions, recovery, and round-trip behavior in the proposed systems.

Does a BAA, transfer clause, or security report close the review?

No. Each may be relevant evidence within a defined relationship or transfer, but none proves every use, recipient, subprocessor, safeguard, onward transfer, architecture, or jurisdiction is lawful, secure, or approved. Keep the applicable data-flow and control questions open until accountable owners close them.

Can evidence from one country support another country?

It may inform the review, but it does not automatically transfer. Compare population, language, care pathway, authority, data source, device and connectivity environment, user, workflow, integration, support, product version, outcome, limitation, and date. Document the local validation and approvals still required.

How should missing evidence be scored?

Use “open — local owner/evidence required,” assign the owner and due date, and identify which decision remains blocked. Do not replace missing evidence with zero, a vendor assertion, an industry average, a framework reference, a default passing score, or a favorable assumption.

What should stop expansion?

Stop when a required legal, privacy, safety, security, integrity, interoperability, audit, support, continuity, recovery, exit, localization, equity, or regulatory gate fails or lacks an authorized owner. Benefits, price, and feature breadth do not offset a hard-stop failure.

Evidence boundary

The cited WHO, OECD, IMDRF, HL7, NIST, EU, EDPB, European Commission, FDA, and HHS materials define frameworks, standards, official policy questions, or jurisdiction-specific requirements only within their stated scopes. They do not establish that a named vendor or product is globally compliant, authorized, certified, clinically validated, interoperable, secure, suitable for a local workflow, supported in every country, or financially beneficial. This article reports no product tests, customer interviews, local measurements, legal conclusions, or procurement approvals; preserve unanswered requests as open gates.